CN1757727A - Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action - Google Patents
Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action Download PDFInfo
- Publication number
- CN1757727A CN1757727A CNA2005100834381A CN200510083438A CN1757727A CN 1757727 A CN1757727 A CN 1757727A CN A2005100834381 A CNA2005100834381 A CN A2005100834381A CN 200510083438 A CN200510083438 A CN 200510083438A CN 1757727 A CN1757727 A CN 1757727A
- Authority
- CN
- China
- Prior art keywords
- kgd
- die body
- iiia
- lys
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A gene clone and expression of the oral gland KGD pattern protein of Japanese lamprey with anti-thrombosis is disclosed. Its cDNA sequence and clone, its relative protein sequence, its expression in colibacillus and Piohia yeast, its combination with the glucoprotein gpIIb/IIIa on cell membrane of platelet to suppress the platelet coagulation, and its application in developing the anti-thrombosis medicines are disclosed.
Description
Technical field
The proteic gene cloning and expression of Japanese lamprey oral gland KGD die body of tool anti thrombotic action belongs to biological technical field, relate in the Japanese lamprey oral gland a proteic cDNA sequence of tool KGD die body and clone, Dui Ying protein sequence and the expression in intestinal bacteria or pichia spp thereof with it, and combine with glycoprotein gpIIb/IIIa specificity on the platelet cell film and the competitive antagonism Fibrinogen combines with hematoblastic, prevented the change of hematoblastic activation and GPIIb/IIIa receptor conformation, the blocking-up acceptor combines with multiple part, thereby the final co-channel of anticoagulant is blocked thrombotic biologic activity.
Background technology
A class medicine that is called " antiplatelet drug " has been used as the effective means for the treatment of thrombotic diseases and has been used widely clinically.Under the normal circumstances, hemostasis in the body, blood coagulation system and fibrinolytic system are in physiologic equilibrium, keep state of normal blood flow.But under some pathologic conditions, during as tunica intima damage or venous blood flow retardance, because platelet activation and adhere to subendothelial tissue, and then cause a series of hemostasis, coagulation process, formed thrombus at last.Thrombocyte particularly plays an important role in the artery thrombosis process at thrombosis.During subcutaneous component, thrombocyte will be activated, and hematoblastic adhesion and gathering take place in blood vessel endothelium infringement exposes.The main component of thrombus is made up of activatory thrombocyte and scleroproein.Therefore, the special anti-activated blood platelet and the medicine of antifibrin can be used as the thrombus directed agents.The antiplatelet antibody of being developed at present mainly prepares at two main sites on the activated blood platelet: 1. 2. GMP140 of GPIIb/IIIa.And the most effective antiplatelet drug is exactly the GPIIb-IIIa antagonist, because no matter by what acceptor, what pathways metabolism, at last must be by the fibrinogen deceptor of GPIIb-IIIa mixture, " gathering " could take place and form thrombus (Huang TF et al. in thrombocyte, 1987) (Shebuski RJ et al., 1989).
KGD
(1-2)Sequence can specificity combines with glycoprotein GPIIb/IIIa specificity on the platelet cell film and the competitive antagonism Fibrinogen combines with hematoblastic, prevented the change of hematoblastic activation and GPIIb/IIIa receptor conformation, the blocking-up acceptor combines with multiple part, thereby the final co-channel of anticoagulant, the formation of blocking-up thrombus.Because KGD die body albumen is platelet glycoprotein GPIIb/IIIa inhibitor, its rely on single-minded combination of the KGD die body that is had with platelet glycoprotein GPIIb/IIIa and with the integrin alpha of vascular endothelial cell surface expression
Vβ
3Binding ability but extremely low or do not have, this characteristic will make KGD die body albumen have potent anti-freezing function, and not have side effects such as haemolysis.This shows that the KGD sequences polypeptide will become the main force in the GPIIb/IIIa antagonist, have the important value of antithrombotic reagent exploitation.
Only in poisonous snake, found the native protein of two kinds of tool KGD die bodys at present at nature: U.S. rattlesnake snake venom barbourin
(1)With agkistrodon halyx pallas venom Ussurista in the Usu
(2), and still unmanned at home and abroad research of the cDNA sequence of the Japanese lamprey oral gland KGD die body albumen Lampetrin4 of this project and protein sequence thereof and function and report, the present invention's discovery that still belongs to the first time in the world.
Reference:
1.Scarborough?RM，Rose?JW，Hsu?MA，Phillips?DR，Fried?VA，Campbell?AM，Nannizzi?L，et?al.Barbourin，a?GPIIb-IIIa-specificintegrin?antagonist?from?the?venom?of?sistrurus?m.barbouri.J?Biol?Chem，1991，266(15)：9359-9362
2.Oshikawa?K?and?Terada?S.Ussuristatin2，a?novel?KGD-bearing?disintegrin?from?Agkistrodon?ussuriensis?venom.J?Biol?Chem，1999，125.
Summary of the invention
Jamprey-ell (Lampetra japonica) belongs to Cyclostomata (Cyclostomata), Peteromyzoni-form, Petromyzonidae, Lampetra, is the most ancient no jaw vertebrates of finding so far.It is the oceanodromous migration fish, and adult is lived in the ocean, is attached on other fish body through sucker commonly used and sucks its blood and meat, and The blood streamed down to make the fish that is adsorbed.This unique life habit of jamprey-ell is hinting in its oral gland to have potent anticoagulant substances.
The invention reside in and from Japanese lamprey oral gland cDNA library, found an open reading frame that can translate KGD (Lys-Gly-Asp) die body, through angling of its mRNA total length being got, finding after the order-checking, bioinformatic analysis, this gene is for to find first at nature, for deriving from the new gene of KGD polypeptide of jamprey-ell.After it being carried out the cDNA clone, its recombinant protein has been carried out efficient abduction delivering in intestinal bacteria.The biologic activity of this KGD recombinant protein relates to the function of platelet aggregation-against and then antithrombotic formation.
The present invention relates in the Japanese lamprey oral gland a proteic cDNA sequence of tool KGD die body and clone, corresponding protein sequence and the expression in intestinal bacteria or pichia spp thereof with it, thereby and the final co-channel of anticoagulant block thrombotic biologic activity.
The present invention is separation and Extraction mRNA from Japanese lamprey oral gland, biological information that obtains the cDNA library that utilization made up from early stage, the EST library and mRNA total length angle the sequencing result of getting to choose open reading frame design primer, adopt the RT-PCR method to obtain a proteic cDNA of KGD and sequence thereof, the present invention also provides the albumen and the sequence thereof of its successful expression in people enterobacteria BL21, the effect of this KGD die body recombinant protein tool platelet aggregation-against can be used as antithrombotic reagent and further develops.
The cDNA sequence 381bp of KGD die body albumen Lampetrin4 is long, and its protein is made up of 127 amino acid, contains a KGD die body, and molecular weight of albumen is 12,954Da.The protein amino acid sequence that its GDNA sequence reaches by its derivation is:
1 atggcctccaggctgcttctacgagcgtctctcaacgccggccgt
M A S R L L L R A S L N A G R
46 cgtgtcgcggccgtcgggagcgtgagaccggcgatgcgagccatg
R V A A V G S V R P A M R A M
91 gcgagcggaggtggcatccccactgatgaagaacaggccacgggc
A S G G G I P T D E E Q A T G
136?ttggagaggttgaccatggaggctaagaaaaaaggcactgacccc
L E R L T M E A K K K G T D P
181?tggagcattgagccacccaagacttacgcaggaaccaaggaagat
W S I E P P K T Y A G T K E D
226?ccacacattgtgccgtccattggtgaaaagcggctgatcggctgc
P H I V P S I G E K R L I G C
271?atctgtgaggaggacaacacagctgtggtgtggttctggctgcac
I C E E D N T A V V W F W L H
316?aagggtgactgccagcgctgcccttcttgtggtgcctcctacaag
K G D C Q R C P S C G A S Y K
361?ctcgttccccacgagctgccgcactga?387
L V P H E L P H *
Lampetrin4 has the effect of inhibition by ADP inductive human platelet aggregation, the IC of its effect in the reorganization KGD of expression in escherichia coli die body albumen
50Be 6.4 μ mol/L.
Description of drawings
Fig. 1 is an experimental procedure schematic flow sheet of the present invention;
Fig. 2 is that reorganization KGD die body albumen Lampetrin4 is to ADP inductive human platelet aggregation restraining effect graphic representation.
Embodiment
The present invention will be further described below in conjunction with accompanying drawing.
1. the extraction of total RNA: the Trizol reagent that adopts GIBCO BRL.Specific as follows:
(1) getting Japanese lamprey oral gland places liquid nitrogen to preserve rapidly;
(2) take by weighing 0.2g poison gland tissue, add the homogenate of 1ml TRIzol reagent preparation poison gland, hatch 5min for 4 ℃;
(3) add the 0.2ml chloroform, the tight lid of lid back is jolting 15sec firmly, places 5min on ice then;
(4) 4 ℃, 12000xg, centrifugal 15min;
(5) upper water is moved into another centrifuge tube mutually, add the 0.5ml Virahol, and hatch 10min on ice;
(6) 4 ℃, 12000xg, centrifugal 15min;
(7) abandon supernatant, in precipitation (containing RNA), add 1ml 75% washing with alcohol, the vortex mixing;
(8) 4 ℃, the centrifugal 5min of 10000xg obtains the RNA precipitation;
(9) after the dry air, with an amount of TE or not have the Rnase water dissolution standby.
2. the primer with design voluntarily carries out the RT-PCR amplification, to obtain the proteic cDNA of Japanese lamprey oral gland KGD die body;
Carry out reverse transcription reaction by following condition: 42 ℃ of 20min, 99 ℃ of 5min, 5 ℃ of 5min
Primer sequence is as follows: P1:5 '-XXcatatggcctccaggctgcttctacga-3 ' P2:5 '-XXaagcttgtgcggcagctcgtggggaac-3 '
3. the purpose cDNA that obtains is connected with the pET23b carrier, is transformed into the Screening and Identification of carrying out positive transformant behind the clone bacterium DH5a;
For generation has histidine-tagged fusion rotein, select pET-23b (+) as gene cloning carrier, clone's concrete operations are as follows:
(1) recovery of goal gene and order-checking: the recovery of goal gene adopts TaKaRa PCR Fragment Recovery Kit to carry out; Check order to reclaiming DNA, this work is finished by the precious biotechnology in Dalian company limited.
(2) extraction of plasmid: adopt precious biological plasmid extraction kit to carry out.
(3) being connected of goal gene dna fragmentation and carrier pET23b: because designed primer has Nde I and Hind III restriction enzyme site respectively, and these two multiple clone site that restriction enzyme site also is pET23b, this makes the possibility that is connected to become of goal gene dna fragmentation and carrier pET23b.
(4) will connect product C aCl
2Method is converted among the clone bacterium E.coli BL21.
(5) Screening and Identification of positive transformant: utilize T
7Universal primer method and double digestion method are carried out the Screening and Identification of positive transformant.
(6) positive recombinant is carried out the IPTG abduction delivering that final concentration is 1mmol/L.The abduction delivering condition is 30 ℃ and spends the night and induce.Expression product called after Lampetrin4;
4. the recombinant protein of expressing is carried out the Histidine affinitive layer purification.
(1) the centrifugal 10min results of 10000g thalline is abandoned supernatant, and raffinate is flowed out as far as possible.The ratio re-suspended cell that adds the ice-cold 1X Binding buffer of 4ml with the original fluid of every 100ml.
(2) above-mentioned sample is placed ultrasonic degradation cell on ice, until solution thickness no longer.
(3) the centrifugal 20min of 14000g is to remove cell debris.
(4) supernatant is with the membrane filtration of 0.45 μ m.
(5) the storage liquid of chamber on the His.Bind Colum is removed in suction, and opens the following mouth of pipe;
(6) the 1xBinding Buffer with 10ml carries out balance to pillar;
(7) will filter sample on the good supernatant liquor;
(8) the 1xBinding Buffer with 10ml washes post;
(9) the 1xWash Buffer with 10ml washes post;
(10) the 1xElute Buffer wash-out target protein of usefulness 5ml.
5. utilization LBY-NJ2 type blood pool instrument utilizes HPRP (PRP) system to carry out platelet aggregation test.
(1) preparation of HPRP (PRP) and platelet poor plasma (PPP)
A) gather the adding of people's empty stomach whole blood and be equipped with in the plastic centrifuge tube of 3.28% Trisodium Citrate BP, the ratio of blood and Trisodium Citrate BP is 9: 1.
B) the centrifugal 5min of 1000rpm room temperature gets the beige supernatant and is HPRP (PRP);
C) surplus liquid is continued with the centrifugal 10min of 4000g room temperature, get supernatant promptly behave poor contain thrombocyte blood plasma (platelet-poor plasma, PPP).
(2) measure the restraining effect of recombinant protein to ADP inductive human platelet aggregation
A) get 2 cuvettes, add each 300 μ l of PPP and PRP respectively, place and assemble 37 ℃ of preheating 5min of instrument,, measure the platelet count among the PRP with PPP school zero.Dilute PRP with PPP then, adjust platelet count to 3 * 10
5/ μ l;
B) with PPP, place 37 ℃ of incubation 3min of LBY-NJ2 type blood pool instrument with the PBS of the adjusted adding of PPP 30ul or the PRP of different concns Lampetrin4;
C) return to zero with PPP;
D) the PRP sample being added final concentration is that the ADP of 3 μ mol/L starts hematoblastic aggregation;
E) turbidimetry for Determination Lampetrin4 measures PAG1 (1min concentration class), PAG3 (3min concentration class), PAG5 (5min concentration class), MA (maximum concentration class) to the restraining effect of platelet aggregation.Get the inhibiting rate of maximum concentration class is mapped as parameter.
Claims (4)
1. the proteic cDNA sequence of KGD (Lys-Gly-Asp) die body that derives from Japanese lamprey oral gland and by the protein amino acid sequence of its derivation, it is characterized in that cDNA sequence 381bp is long, its protein is made up of 127 amino acid, contain a KGD (Lys-Gly-Asp) die body, molecular weight of albumen is 12,954Da.This KGD die body albumen is named as Lampetrin4, and the protein amino acid sequence that its cDNA sequence reaches by its derivation is:
1?atggcctccaggctgcttctacgagcgtctctcaacgccggccgt
M A S R L L L R A S L N A G R
46?cgtgtcgcggccgtcgggagcgtgagaccggcgatgcgagccatg
R V A A V G S V R P A M R A M
91?gcgagcggaggtggcatccccactgatgaagaacaggccacgggc
A S G G G I P T D E E Q A T G
136?ttggagaggttgaccatggaggctaagaaaaaaggcactgacccc
L E R L T M E A K K K G T D P
181?tggagcattgagccacccaagacttacgcaggaaccaaggaagat
W S I E P P K T Y A G T K E D
226?ccacacattgtgccgtccattggtgaaaagcggctgatcggctgc
P H I V P S I G E K R L I G C
271?atctgtgaggaggacaacacagctgtggtgtggttctggctgcac
I C E E D N T A V V W F W L H
316?aagggtgactgccagcgctgcccttcttgtggtgcctcctacaag
K G D?C Q R C P S C G A S Y K
361?ctcgttccccacgagctgccgcactga?387
L V P H E L P H *
2. the proteic cDNA of KGD (Lys-Gly-Asp) die body that derives from Japanese lamprey oral gland according to claim 1 is connected in the gene clone product (recombinant plasmid) of any kind carrier and the recombinant protein of expressing thereof.The foreign gene that it is characterized in that gene clone is the Lampetrin4 gene, and the expressed recombinant protein that gets contains the KGD die body.
3. the gene clone product that derives from the proteic cDNA of KGD (Lys-Gly-Asp) die body of Japanese lamprey oral gland according to claim 2 is connected in the application of the anti-thrombus function of the expressed recombinant protein of any kind carrier.It is characterized in that the KGD polypeptide is a platelet glycoprotein GPIIb/IIIa inhibitor, it relies on the KGD die body specificity that is had to combine with platelet glycoprotein GPIIb/IIIa, the competitive antagonism Fibrinogen combines with hematoblastic, prevented the change of hematoblastic activation and GPIIb/IIIa receptor conformation, blocking-up GPIIb/IIIa acceptor combines with multiple part, thereby the final co-channel that has suppressed platelet aggregation, the formation of blocking-up thrombus.This characteristic makes Lampetrin4 have anti-freezing, the anti-thrombus function of potent low toxicity.
4. the proteic cDNA point mutation of KGD (Lys-Gly-Asp) die body or the product of the genetic modification that base is inserted or lacked and the recombinant protein of expression thereof that derives from Japanese lamprey oral gland according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100834381A CN1293193C (en) | 2005-07-13 | 2005-07-13 | Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100834381A CN1293193C (en) | 2005-07-13 | 2005-07-13 | Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1757727A true CN1757727A (en) | 2006-04-12 |
| CN1293193C CN1293193C (en) | 2007-01-03 |
Family
ID=36703295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100834381A Expired - Fee Related CN1293193C (en) | 2005-07-13 | 2005-07-13 | Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1293193C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1995345B (en) * | 2006-08-31 | 2010-12-29 | 辽宁师范大学 | Recombinant L-251 protein with anti-inflammatory effect secreted by Japanese lamprey oral gland |
| CN101195656B (en) * | 2006-12-08 | 2012-05-09 | 辽宁师范大学 | Recombined Japanese lamprey glandulae oris excreted L-250 protein anticoagulant efficacy |
| CN103694330A (en) * | 2013-11-25 | 2014-04-02 | 辽宁师范大学 | Preparation method of affinity chromatography purification tag-free genetic recombinant lamprey Lj-RGD3 protein |
| CN108004244A (en) * | 2017-12-22 | 2018-05-08 | 辽宁师范大学 | The method of lamprey nerve axis body tissue specificity expression promoter LIP-P and construction of recombinant plasmid vector |
| CN108187030A (en) * | 2018-01-31 | 2018-06-22 | 辽宁师范大学 | Recombinant peptide rLj-RGD3 is preparing the application in preventing and treating acute myocardial infarction AMI drug |
-
2005
- 2005-07-13 CN CNB2005100834381A patent/CN1293193C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1995345B (en) * | 2006-08-31 | 2010-12-29 | 辽宁师范大学 | Recombinant L-251 protein with anti-inflammatory effect secreted by Japanese lamprey oral gland |
| CN101195656B (en) * | 2006-12-08 | 2012-05-09 | 辽宁师范大学 | Recombined Japanese lamprey glandulae oris excreted L-250 protein anticoagulant efficacy |
| CN103694330A (en) * | 2013-11-25 | 2014-04-02 | 辽宁师范大学 | Preparation method of affinity chromatography purification tag-free genetic recombinant lamprey Lj-RGD3 protein |
| CN103694330B (en) * | 2013-11-25 | 2016-01-06 | 辽宁师范大学 | Go the preparation method of the recombinant lamprey Lj-RGD3 albumen of affinitive layer purification label |
| CN108004244A (en) * | 2017-12-22 | 2018-05-08 | 辽宁师范大学 | The method of lamprey nerve axis body tissue specificity expression promoter LIP-P and construction of recombinant plasmid vector |
| CN108187030A (en) * | 2018-01-31 | 2018-06-22 | 辽宁师范大学 | Recombinant peptide rLj-RGD3 is preparing the application in preventing and treating acute myocardial infarction AMI drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1293193C (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mahmoud et al. | Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. | |
| CN1293193C (en) | Gene clone of and expression Japan lamprey oral cavity gland KGD model protein possessing anti thrombotic action | |
| CN1314807C (en) | Gene clone and expression of RGD die body protein of oral gland in Japan lamprey possessing function for anti tumour | |
| CN107446036A (en) | A kind of enrichment method of platelet cell factor concentration matter | |
| CN108220274A (en) | A kind of preparation and application of high activity plasma thromboplastin antecedent mutant and its gene therapy/editor's carrier, recombination/fusion protein | |
| CN1134451C (en) | Inhibitor of collagen-stimulated platelet aggregation | |
| Eggestøl et al. | Interleukin-1 ligands and receptors in lumpfish (Cyclopterus lumpus L.): Molecular characterization, phylogeny, gene expression, and transcriptome analyses | |
| CN1197587C (en) | Application of position-N desulfurizing heparin in preventing and treating inflammation | |
| CN1284797C (en) | Method for constructing, expressing and purifying human recombination factor and application | |
| Liu et al. | The effect of tumour necrosis factor-α on periodontal ligament stem cell differentiation and the related signaling pathways | |
| JP2002508953A (en) | Polypeptides, their DNA codes, their preparation and their use in inhibiting factor XII activation | |
| CN101195656B (en) | Recombined Japanese lamprey glandulae oris excreted L-250 protein anticoagulant efficacy | |
| CN1240719C (en) | New-type bifunctional hirudin and its preparation method and application | |
| CN101033253A (en) | Recombination Japanese lamprey oral gland Grimin protein induction cell apoptosis and its antineoplastic action | |
| CN102732524B (en) | Use of histidine-rich glycoprotein (HRG)-like lampetra japonica Lj-RGD3 all RGD deletion mutant Lj-112 in antitumor drug | |
| JP2002514606A (en) | Use of interferon alpha 5 for the treatment of viral liver disease | |
| CN1800384A (en) | Procalcitonin preparation method | |
| CN100335499C (en) | C-terminal amino acid lactone modified extrasin alpha-1 and its uses | |
| CN1157406C (en) | Novel, ATP-sensitive potassium-channel proteins and genes for the same | |
| CN100432102C (en) | Blood platelet reinforcing protein and application thereof | |
| CN1473061A (en) | Antithrombotic compositions | |
| Afzal et al. | Role of Interleukin 10 in Hepatitis C Viral Clearance and Distribution of its Polymorphism in Pakistani Population | |
| CN1920029A (en) | Human tissue factor pathway inhibitory factor mutation gene mTFPI, recombination carrier including the same and host cell thereof | |
| CN1323713C (en) | Novel usage of soluble P-lectin and anthrax lethal toxin | |
| CN1810258A (en) | Compound hemostatic originated from venom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20200713 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |